ArticleEClinicalMedicine2022

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.

Joon Young Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.